Abstracts tagged "Biologic agents"

Abstract Number: 402 • 2016 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen², Melissa Mannion⁴, Kenneth G. Saag⁵, Jie Zhang⁶ and Jeffrey R. Curtis⁵, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁵Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The comparative risk of infection with newer biologic agents, such as abatacept (ABA), in the treatment of juvenile idiopathic arthritis (JIA) has not been…
Abstract Number: 1673 • 2016 ACR/ARHP Annual Meeting
Characteristic Phenotypes of Peripheral T Cells and Efficacy of Biological Dmards in Patients with Psoriatic Arthritis
Ippei Miyagawa¹, Shingo Nakayamada², Satoshi Kubo³, Kazuhisa Nakano², Yusuke Miyazaki³, Maiko Yoshikawa⁴ and Yoshiya Tanaka⁵, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biological DMARDs (bDMARDs) such as adalimumab (ADA), infliximab (IFX), ustekinumab (UST) and secukinumab (SEC) become available and efficacious in patients with psoriatic arthritis (PsA).…
Abstract Number: 2333 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Outcomes of Total Ankle Arthroplasty Between Biologics and NON-Biologics Treatment Groups in Patients with Rheumatoid Arthritis
Makoto Hirao¹, Kosuke Ebina², Takaaki Noguchi³, Hideki Tsuboi⁴, Jun Hashimoto⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁴Osaka Rosai Hospital, Sakai, Japan, ⁵Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: In progress of medical treatment against rheumatoid arthritis (RA) disease activity using methotrexate (MTX) and/or biologics, we often see cases that require surgical intervention…
Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting
Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Liliana Uribe Botero¹, Margarita A Saldarriaga Alvarez¹, Natalia Duque Zapata¹, Johnny Urrego¹, Oscar Jair Felipe Diaz¹, Carmen Cerón², Alejandro Uribe¹, Luis Alonso Gonzalez^1,3 and José A. Gómez-Puerta¹, ¹Medicarte IPS, Medellín, Colombia, Medellín, Colombia, ²Medicarte IPS, Medellín, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
Abstract Number: 3L • 2015 ACR/ARHP Annual Meeting
A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
Athimalaipet V Ramanan¹, Andrew D. Dick², Andrew McKay³, Ashley Jones⁴, Paula Williamson⁴, Sandrine Compeyrot-Lacassagne⁵, Ben Hardwick⁴, Helen Hickey⁴, Dyfrig Hughes⁶, Patricia Woo⁵, Diana Benton¹, Clive Edelsten⁵ and Michael W. Beresford⁷, ¹University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ²University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ³Biostatistics, Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁴Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Bangor University, Bangor, United Kingdom, ⁷University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Uveitis associated with Juvenile Idiopathic Arthritis (JIA) is a major cause of morbidity with potentially sight-threatening complications. Despite current screening and (pre-biologic) therapeutic options,…
Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 144 • 2015 ACR/ARHP Annual Meeting
One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis
Tao Gu¹, Derek Tang², Gaurav Deshpande¹, Debra F Eisenberg¹ and David J. Harrison³, ¹HealthCore, Wilmington, DE, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Switching a biologic treatment or escalating biologic doses are common approaches used upon biologic treatment failure. The objective of this study was to estimate…
Abstract Number: 586 • 2015 ACR/ARHP Annual Meeting
Titer of Anti-Citrullinated Peptide Antibody Affects the Efficacy of First Biological Treatment in Rheumatoid Arthritis
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Anti-citrullinated protein antibody (ACPA) has been an important marker in diagnosing rheumatoid arthritis (RA). Its predictive value remains unclear; therefore, here we investigated whether…
Abstract Number: 1416 • 2015 ACR/ARHP Annual Meeting
Postoperative Complications Rate in Orthopaedic Surgery Performed in Rheumatic Patients in Use of Biologic Agents
Clarissa Queiroz Pimentel¹, Luiz Eduardo de Paula¹, Ana Paula Luppino-Assad², Gilberto Luis Camanho³, Eloisa Bonfá⁴ and Marco Antonio Gonçalves Pontes Filho¹, ¹Division of Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, ²Division of Rheumatology, University of São Paulo, sao paulo, Brazil, ³Division of Orthopedics, University of São Paulo Medical School, São Paulo, Brazil, ⁴Rheumatology, University of São Paulo, São Paulo, Brazil, Sao Paulo, Brazil
Background/Purpose: Biologic agents have been associated with an increased risk of infection, thrombosis and delayed wound healing. However, there is no definitive consensus on suspension…
Abstract Number: 2148 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Philip J. Mease¹, Iain B. McInnes², Bruce Kirkham³, Arthur Kavanaugh⁴, Proton Rahman⁵, Désirée van der Heijde⁶, Robert B.M. Landewé⁷, P Nash⁸, Luminita Pricop⁹, Zailong Wang¹⁰ and Shephard Mpofu¹¹, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁴University of California, San Diego School of Medicine, LaJolla, CA, ⁵Medicine, Memorial University, St John's, NF, Canada, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁸Department of Medicine, University of Queensland, Brisbane, Australia, ⁹Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: In the Phase 3, randomized, double-blind, placebo (PBO)-controlled, FUTURE 1 study (NCT01392326), the anti–interleukin-17A monoclonal antibody secukinumab provided rapid and significant improvements in key…
Abstract Number: 2874 • 2015 ACR/ARHP Annual Meeting
Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Leonardo Santo¹, Angelo Semeraro², Carmelo Zuccaro³, Maria Grazia Anelli⁴, Romano Bucci⁵, Antonio Marsico⁶, Laura Quarta⁷, Giorgio Carlino⁸, Francesco Paolo Cantatore⁹, Annamaria Gaudio¹⁰, Fabio Cacciapaglia¹¹, Oriana Casilli¹², Paola Chiara Francesca Falappone¹³ and Florenzo Iannone¹⁴, ¹DSS4 Barletta, ASL BT Andria - Rheumatology Service, Barletta, Italy, ²Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ³U.O.of Geriatrics, Outpatient clinic of Rheumatology, Brindisi, Italy, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵A.O.U., Rheumatology Hospital Unit, Foggia, Italy, ⁶Outpatient clinic of Rheumatology, Taranto,, Italy, ⁷Department of Rheumatology, "V.Fazzi" Hospital, San Cesario di Lecce, Italy, ⁸ASL LE - DSS Casarano and Gallipoli, Rheumatology Service, Gallipoli, Italy, ⁹Department of Rheumatology, University of Foggia,, Foggia, Italy, ¹⁰Department of Rheumatology, University of Foggia, Foggia, Italy, ¹¹Internal Medicine Unit and Outpatient clinic of Rheumatology, “N. Melli” Hospital, San Pietro Vernotico (BR), Italy, ¹²Department of Rheumatology, "Vito Fazzi" Hospital, San Cesario di Lecce, Italy, ¹³Internal Medicine Unit - Outpatient clinic of Rheumatology,, "S. Camillo de' Lellis" Hospital, Mesagne (BR), Italy, ¹⁴Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy
Background/Purpose: It has previously been shown that the survival of anti-TNF drugs was lower in Rheumatoid arthritis (RA) than in other chronic arthritis1. The objective…
Abstract Number: 145 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis
Zheng-Yi Zhou¹, Jenny Griffith², Arijit Ganguli², Ella Xiaoyan Du¹ and Keith Betts¹, ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Real world studies comparing the healthcare utilization of anti-TNFs vs. non-TNFs as the next alternative after the failure of the first anti-TNF are scarce.…
Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Jeffrey R. Curtis¹, Ying Shan², Joel M. Kremer³, Katherine Saunders⁴, Dennis Parenti⁵ and Shelly Kafka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²UMass Memorial Medical Center, Worcester, MA, ³Albany Medical College, Albany, NY, ⁴Corrona LLC, Atlanta, GA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
Abstract Number: 1537 • 2015 ACR/ARHP Annual Meeting
Effect of TNF-Alpha Blockade on Body Composition in Inflammatory Rheumatic Disease: Systematic Review with Meta-Analysis
sarah marouen¹, Thomas Barnetche², Bernard Combe³, Jacques Morel⁴ and Claire I. Daien⁴, ¹Rhumatology Department, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Patients with chronic inflammatory rheumatic disease have elevated circulating concentrations of TNF-alpha and other pro-inflammatory cytokines that can modify body composition. Metabolic changes are…
Abstract Number: 2326 • 2015 ACR/ARHP Annual Meeting
Patient Preferences Regarding Route of Biologic Administration in an Inflammatory Arthritis Cohort
Alysia Kwiatkowski¹, Lucas Grisanti², Joseph Grisanti³ and James Hatem⁴, ¹Internal Medicine, Albany Medical Center, Albany, NY, ²Department of Biology, College of Wooster, Wooster, OH, ³Buffalo Rheumatology and Medicine, Orchard Park, NY, ⁴BioStatistics, Buffalo Rheumatology and Medicine, Orchard Park, NY
Background/Purpose: Multiple biologic treatment modalities are available for managing systemic inflammatory disease states. Patient preference regarding routes of administration is frequently unclear and has not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].